PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30038488-3 2018 Western blot analysis was performed to identify the effect of nimotuzumab and/or celecoxib with or without irradiation on the cytoplasmic and nuclear EGFR signaling pathways in CNE2 cells. Celecoxib 81-90 epidermal growth factor receptor Homo sapiens 150-154 33164600-9 2021 Mechanistically, Celecoxib and Afatinib-treated cells showed the inhibition of COX-2 and EGFR expression, which may responsible for the A549 cells increased resistance to radiation. Celecoxib 17-26 epidermal growth factor receptor Homo sapiens 89-93 33116404-0 2020 Novel Molecular Mechanism of Aspirin and Celecoxib Targeting Mammalian Neuraminidase-1 Impedes Epidermal Growth Factor Receptor Signaling Axis and Induces Apoptosis in Pancreatic Cancer Cells. Celecoxib 41-50 epidermal growth factor receptor Homo sapiens 95-127 32658799-4 2020 Because papilloma cells overexpress the epidermal growth factor receptor (EGFR), together with an increased expression of COX-2 and prostaglandin E2, the combination of erlotinib and celecoxib seems plausible, and could be proposed for patients with poor response to previous lines of treatment. Celecoxib 183-192 epidermal growth factor receptor Homo sapiens 40-72 32658799-4 2020 Because papilloma cells overexpress the epidermal growth factor receptor (EGFR), together with an increased expression of COX-2 and prostaglandin E2, the combination of erlotinib and celecoxib seems plausible, and could be proposed for patients with poor response to previous lines of treatment. Celecoxib 183-192 epidermal growth factor receptor Homo sapiens 74-78 30066906-14 2018 In conclusion, the combined inhibition of EGFR and COX-2 by gefitinib and celecoxib may overcome docetaxel resistance in human CRPC. Celecoxib 74-83 epidermal growth factor receptor Homo sapiens 42-46 28450158-8 2017 The simultaneous suppression of ErbB kinases and androgen signaling by Celecoxib represents a novel strategy to interrupt the vicious cycle of AR/ErbB cross-talk with the primary purpose of undermining their resilient signaling in prostate cancer progression. Celecoxib 71-80 epidermal growth factor receptor Homo sapiens 32-36 30038944-1 2018 Recent work suggests the selective Cox-2 inhibitor celecoxib delays progression to androgen independence in hormone sensitive prostate cancer (HSPC) through inhibition of the androgen receptor (AR) and ErbB signaling. Celecoxib 51-60 epidermal growth factor receptor Homo sapiens 202-206 28450158-0 2017 The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer. Celecoxib 63-72 epidermal growth factor receptor Homo sapiens 4-8 28450158-2 2017 The purpose of this work was to determine the ability of the COX-2 inhibitor Celecoxib to modulate the EGFR-AR signaling pathway in androgen-dependent PCa cells and to provide a rationale for its beneficial use in chemopreventive strategies. Celecoxib 77-86 epidermal growth factor receptor Homo sapiens 103-107 28450158-8 2017 The simultaneous suppression of ErbB kinases and androgen signaling by Celecoxib represents a novel strategy to interrupt the vicious cycle of AR/ErbB cross-talk with the primary purpose of undermining their resilient signaling in prostate cancer progression. Celecoxib 71-80 epidermal growth factor receptor Homo sapiens 146-150 28450158-5 2017 We found that Celecoxib, through EGF and amphiregulin (AREG) induction, caused EGFR and ErbB2 activation and consequent degradation associated with the inhibition of androgenic signaling. Celecoxib 14-23 epidermal growth factor receptor Homo sapiens 79-83 28282799-1 2017 BACKGROUND: Radiosensitivity by blocking the epidermal growth factor receptor and cyclooxygenase-2 pathways with erlotinib and celecoxib in A549 human lung cancer cell was investigated. Celecoxib 127-136 epidermal growth factor receptor Homo sapiens 45-77 28423516-1 2017 Here we showed that the addition of the COX-2 inhibitor celecoxib improved the antitumor efficacy in colorectal cancer (CRC) of the monoclonal anti-EGFR antibody cetuximab. Celecoxib 56-65 epidermal growth factor receptor Homo sapiens 148-152 28423516-8 2017 In summary, our study shows that the addition of celecoxib enhances the antitumor efficacy of cetuximab in CRC due to impairment of EGFR-RAS-FOXM1-beta-catenin signaling axis. Celecoxib 49-58 epidermal growth factor receptor Homo sapiens 132-136 27508092-0 2016 Celecoxib-erlotinib combination delays growth and inhibits angiogenesis in EGFR-mutated lung cancer. Celecoxib 0-9 epidermal growth factor receptor Homo sapiens 75-79 27508092-4 2016 In NSCLC cells harboring epidermal growth factor receptor (EGFR) mutations, combination celecoxib-erlotinib treatment led to synergistic cell death, but there was minimal efficacy in NSCLC cells with wild-type EGFR. Celecoxib 88-97 epidermal growth factor receptor Homo sapiens 25-57 27508092-4 2016 In NSCLC cells harboring epidermal growth factor receptor (EGFR) mutations, combination celecoxib-erlotinib treatment led to synergistic cell death, but there was minimal efficacy in NSCLC cells with wild-type EGFR. Celecoxib 88-97 epidermal growth factor receptor Homo sapiens 59-63 27508092-4 2016 In NSCLC cells harboring epidermal growth factor receptor (EGFR) mutations, combination celecoxib-erlotinib treatment led to synergistic cell death, but there was minimal efficacy in NSCLC cells with wild-type EGFR. Celecoxib 88-97 epidermal growth factor receptor Homo sapiens 210-214 26033830-9 2015 Among the patients treated with celecoxib, those with wild-type EGFR were found to have an increased PFS (3.2 months vs 1.8 months; P = .03). Celecoxib 32-41 epidermal growth factor receptor Homo sapiens 64-68 26033830-13 2015 Patients with EGFR wild-type status may benefit from the combination of erlotinib and celecoxib. Celecoxib 86-95 epidermal growth factor receptor Homo sapiens 14-18 25595386-0 2015 Epidermal growth factor receptor-targeted immunoliposomes for delivery of celecoxib to cancer cells. Celecoxib 74-83 epidermal growth factor receptor Homo sapiens 0-32 26107817-4 2015 The dual tyrosine kinase inhibitor AEE788 and celecoxib were used to inhibit EGFR/VEGFR and COX-2, respectively, in colorectal cancer cells. Celecoxib 46-55 epidermal growth factor receptor Homo sapiens 77-81 26464643-0 2015 Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells. Celecoxib 134-143 epidermal growth factor receptor Homo sapiens 161-165 26464643-13 2015 There was increased down regulation of COX-2 and p-EGFR when both cell lines were treated with high-concentration celecoxib plus gefitinib compared to either agent alone. Celecoxib 114-123 epidermal growth factor receptor Homo sapiens 51-55 26464643-14 2015 This study demonstrates that high serum COX-2 levels may indicate EGFR mutations and that the efficacy of combined celecoxib and gefitinib is significantly greater in NSCLC cells with EGFR mutations; at high concentrations, the combination is efficacious in wild-type NSCLC cells. Celecoxib 115-124 epidermal growth factor receptor Homo sapiens 184-188 25987127-0 2015 Celecoxib increases EGF signaling in colon tumor associated fibroblasts, modulating EGFR expression and degradation. Celecoxib 0-9 epidermal growth factor receptor Homo sapiens 84-88 25987127-3 2015 We found that a 24-48h Celecoxib priming increased EGF receptor (EGFR) mRNA and protein levels in colon TAFs, promoting EGF binding and internalization. Celecoxib 23-32 epidermal growth factor receptor Homo sapiens 51-63 25987127-3 2015 We found that a 24-48h Celecoxib priming increased EGF receptor (EGFR) mRNA and protein levels in colon TAFs, promoting EGF binding and internalization. Celecoxib 23-32 epidermal growth factor receptor Homo sapiens 65-69 25987127-4 2015 Celecoxib-primed TAFs showed a reduced EGFR degradation after EGF challenge. Celecoxib 0-9 epidermal growth factor receptor Homo sapiens 39-43 25987127-7 2015 Cytoplasmic vesicles fractionation showed a reduced maturation of Cathepsin-D in late endosomes and an increased content of EGFR and Rab7 in lysosomes of Celecoxib-treated TAFs.Our data indicate a double mechanism mediating the increased response to EGF of colon TAFs treated with Celecoxib. Celecoxib 154-163 epidermal growth factor receptor Homo sapiens 124-128 25776499-8 2015 We found that treatment of cetuximab (C225), a monoclonal anti-epidermal growth factor receptor (EGFR) antibody, with low-dose celecoxib results in a more pronounced anticancer effect in HNSCC than either agent alone. Celecoxib 127-136 epidermal growth factor receptor Homo sapiens 58-95 25776499-8 2015 We found that treatment of cetuximab (C225), a monoclonal anti-epidermal growth factor receptor (EGFR) antibody, with low-dose celecoxib results in a more pronounced anticancer effect in HNSCC than either agent alone. Celecoxib 127-136 epidermal growth factor receptor Homo sapiens 97-101 25595386-8 2015 EGFR-targeted ILs, having an average size of 120nm, could encapsulate 40% of the CLX, while providing a sustained drug release profile. Celecoxib 81-84 epidermal growth factor receptor Homo sapiens 0-4 25595386-10 2015 In addition, the CLX-loaded-anti-EGFR immunoliposomes were significantly more toxic compared to the non-targeted ones in cancer cells with EGFR-overexpression but not in the cells with low EGFR expression, regardless of their COX-2 expression status. Celecoxib 17-20 epidermal growth factor receptor Homo sapiens 33-37 25595386-10 2015 In addition, the CLX-loaded-anti-EGFR immunoliposomes were significantly more toxic compared to the non-targeted ones in cancer cells with EGFR-overexpression but not in the cells with low EGFR expression, regardless of their COX-2 expression status. Celecoxib 17-20 epidermal growth factor receptor Homo sapiens 139-143 25595386-10 2015 In addition, the CLX-loaded-anti-EGFR immunoliposomes were significantly more toxic compared to the non-targeted ones in cancer cells with EGFR-overexpression but not in the cells with low EGFR expression, regardless of their COX-2 expression status. Celecoxib 17-20 epidermal growth factor receptor Homo sapiens 139-143 25595386-11 2015 Thus, selective targeting of CLX with anti-EGFR immunoliposomes appears to be a promising strategy for therapy of tumors that overexpress EGFR. Celecoxib 29-32 epidermal growth factor receptor Homo sapiens 43-47 25595386-11 2015 Thus, selective targeting of CLX with anti-EGFR immunoliposomes appears to be a promising strategy for therapy of tumors that overexpress EGFR. Celecoxib 29-32 epidermal growth factor receptor Homo sapiens 138-142 25328959-1 2014 The aim of the present study was to evaluate the potency of epidermal growth factor receptor (EGFR) pathway inhibition achieved by combining cetuximab (CET), an anti-EGFR monoclonal antibody, and celecoxib (CXB), a cyclooxygenase-2 (COX-2) inhibitor, in oral squamous cell carcinoma (OSCC) in vitro and in vivo. Celecoxib 196-205 epidermal growth factor receptor Homo sapiens 60-92 25328959-1 2014 The aim of the present study was to evaluate the potency of epidermal growth factor receptor (EGFR) pathway inhibition achieved by combining cetuximab (CET), an anti-EGFR monoclonal antibody, and celecoxib (CXB), a cyclooxygenase-2 (COX-2) inhibitor, in oral squamous cell carcinoma (OSCC) in vitro and in vivo. Celecoxib 196-205 epidermal growth factor receptor Homo sapiens 94-98 25328959-1 2014 The aim of the present study was to evaluate the potency of epidermal growth factor receptor (EGFR) pathway inhibition achieved by combining cetuximab (CET), an anti-EGFR monoclonal antibody, and celecoxib (CXB), a cyclooxygenase-2 (COX-2) inhibitor, in oral squamous cell carcinoma (OSCC) in vitro and in vivo. Celecoxib 207-210 epidermal growth factor receptor Homo sapiens 60-92 25328959-1 2014 The aim of the present study was to evaluate the potency of epidermal growth factor receptor (EGFR) pathway inhibition achieved by combining cetuximab (CET), an anti-EGFR monoclonal antibody, and celecoxib (CXB), a cyclooxygenase-2 (COX-2) inhibitor, in oral squamous cell carcinoma (OSCC) in vitro and in vivo. Celecoxib 207-210 epidermal growth factor receptor Homo sapiens 94-98 24528083-5 2014 Western blotting showed decreased expression of P-EGFR and COX-2 with both erlotinib and celecoxib treatments, but most pronouncedly in the combined group (P<0.05). Celecoxib 89-98 epidermal growth factor receptor Homo sapiens 50-54 24591842-6 2014 Exposure to celecoxib (21.8 mumol/L) plus 5-fluorouracil (8.1 x 10(-3) g/L) or sorafenib (4.4 mumol/L) increased apoptosis but exerted no effect on COX2, phosphorylated epidermal growth-factor receptor (p-EGFR) and phosphorylated (p)-AKT expression. Celecoxib 12-21 epidermal growth factor receptor Homo sapiens 169-201 25198789-1 2014 The aim of the present study was to evaluate the potency of epidermal growth factor receptor (EGFR) pathway inhibition achieved by combining cetuximab (CET), an anti-EGFR monoclonal antibody, and celecoxib (CXB), a cyclooxygenase-2 (COX-2) inhibitor, in oral squamous cell carcinoma (OSCC) in vitro and in vivo. Celecoxib 196-205 epidermal growth factor receptor Homo sapiens 60-92 25198789-1 2014 The aim of the present study was to evaluate the potency of epidermal growth factor receptor (EGFR) pathway inhibition achieved by combining cetuximab (CET), an anti-EGFR monoclonal antibody, and celecoxib (CXB), a cyclooxygenase-2 (COX-2) inhibitor, in oral squamous cell carcinoma (OSCC) in vitro and in vivo. Celecoxib 196-205 epidermal growth factor receptor Homo sapiens 94-98 25198789-1 2014 The aim of the present study was to evaluate the potency of epidermal growth factor receptor (EGFR) pathway inhibition achieved by combining cetuximab (CET), an anti-EGFR monoclonal antibody, and celecoxib (CXB), a cyclooxygenase-2 (COX-2) inhibitor, in oral squamous cell carcinoma (OSCC) in vitro and in vivo. Celecoxib 207-210 epidermal growth factor receptor Homo sapiens 60-92 25198789-1 2014 The aim of the present study was to evaluate the potency of epidermal growth factor receptor (EGFR) pathway inhibition achieved by combining cetuximab (CET), an anti-EGFR monoclonal antibody, and celecoxib (CXB), a cyclooxygenase-2 (COX-2) inhibitor, in oral squamous cell carcinoma (OSCC) in vitro and in vivo. Celecoxib 207-210 epidermal growth factor receptor Homo sapiens 94-98 24085777-13 2014 Encouraging responses to the celecoxib and erlotinib combination correlated with EGFR pathway inhibition. Celecoxib 29-38 epidermal growth factor receptor Homo sapiens 81-85 23422093-9 2013 CONCLUSION: Treatment with erlotinib combined with celecoxib offers an effective chemopreventive approach through inhibition of EGFR and mTOR pathways, which may serve as potential biomarkers to monitor the intervention of this combination in the clinic. Celecoxib 51-60 epidermal growth factor receptor Homo sapiens 128-132 23010081-0 2013 Celecoxib induces proliferation and Amphiregulin production in colon subepithelial myofibroblasts, activating erk1-2 signaling in synergy with EGFR. Celecoxib 0-9 epidermal growth factor receptor Homo sapiens 143-147 23010081-9 2013 Our data provide evidence that Celecoxib directly activates MF empowering EGFR signaling. Celecoxib 31-40 epidermal growth factor receptor Homo sapiens 74-78 23010081-10 2013 According to these results the association with EGFR (or erk1-2) inhibitors could abolish the off-target activity of Celecoxib, possibly extending the potential of this drug for colon cancer prevention. Celecoxib 117-126 epidermal growth factor receptor Homo sapiens 48-52 23483082-6 2011 Concurrent treatment with celecoxib and erlotinib +- IR inhibited multiple prosurvival proteins including p-ERK1/2, p-EGFR, p-AKT, p-STAT3, COX-2 and PGE-2. Celecoxib 26-35 epidermal growth factor receptor Homo sapiens 118-122 23483082-7 2011 The combination of celecoxib, erlotinib and IR is a promising strategy to overcoming resistance to combined EGFR inhibition and IR alone. Celecoxib 19-28 epidermal growth factor receptor Homo sapiens 108-112 23483082-2 2011 We hypothesize that combined EGFR and cyclooxygenase-2 (COX-2) inhibition, using small molecule inhibitors erlotinib and celecoxib, respectively would further increase the antitumor activity of radiotherapy. Celecoxib 121-130 epidermal growth factor receptor Homo sapiens 29-33 17996386-0 2008 Celecoxib induced tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA-repair: a COX-2 independent mechanism. Celecoxib 0-9 epidermal growth factor receptor Homo sapiens 88-92 19736197-5 2009 Because papillomas overexpress epidermal growth factor receptor, along with increased expression of cyclooxygenase-2 and prostaglandin E2, it was reasoned that a combination therapy of erlotinib and celecoxib would be effective in controlling papilloma growth. Celecoxib 199-208 epidermal growth factor receptor Homo sapiens 31-63 17996386-5 2008 The observed radiosensitization could neither be correlated with basal COX-2 expression pattern nor with basal production of prostaglandin E2, but was depended on the ability of celecoxib to inhibit basal and radiation-induced nuclear transport of epidermal growth factor receptor (EGFR). Celecoxib 178-187 epidermal growth factor receptor Homo sapiens 248-280 17996386-5 2008 The observed radiosensitization could neither be correlated with basal COX-2 expression pattern nor with basal production of prostaglandin E2, but was depended on the ability of celecoxib to inhibit basal and radiation-induced nuclear transport of epidermal growth factor receptor (EGFR). Celecoxib 178-187 epidermal growth factor receptor Homo sapiens 282-286 17996386-6 2008 The nuclear EGFR transport was strongly inhibited in A549-, HSF7-, and COX-2-deficient HCT116 cells, which were radiosensitized, but not in FaDu and HH4dd cells, which resisted celecoxib-induced radiosensitization. Celecoxib 177-186 epidermal growth factor receptor Homo sapiens 12-16 17996386-9 2008 CONCLUSIONS: Celecoxib enhanced radiosensitivity by inhibition of EGFR-mediated mechanisms of radioresistance, a signaling that was independent of COX-2 activity. Celecoxib 13-22 epidermal growth factor receptor Homo sapiens 66-70 17948911-11 2007 CONCLUSIONS: The results of the current study demonstrate that the effectiveness of the addition of celecoxib to an EGFR-TKI is significantly greater in NSCLC cells with EGFR mutations, which is likely due to more complete inhibition of both pathways. Celecoxib 100-109 epidermal growth factor receptor Homo sapiens 116-120 18172786-7 2008 Celecoxib single agent could also inhibit AKT and ERK pathway in NSCLC, even the EGFR expression under high concentration treatment. Celecoxib 0-9 epidermal growth factor receptor Homo sapiens 81-85 17948911-11 2007 CONCLUSIONS: The results of the current study demonstrate that the effectiveness of the addition of celecoxib to an EGFR-TKI is significantly greater in NSCLC cells with EGFR mutations, which is likely due to more complete inhibition of both pathways. Celecoxib 100-109 epidermal growth factor receptor Homo sapiens 170-174 17505004-2 2007 The combination of cyclooxygenase-2 inhibitors and epidermal growth factor receptor tyrosine kinase inhibitors, such as celecoxib and ZD1839 (gefitinib), was reported to achieve synergistic cell growth inhibition in squamous cell carcinoma of the head and neck. Celecoxib 120-129 epidermal growth factor receptor Homo sapiens 51-83 17409801-3 2007 Preclinical studies have suggested that celecoxib, a cyclooxygenase-2 inhibitor, has antitumor activity in NSCLC and can enhance the activity of EGFR inhibitors. Celecoxib 40-49 epidermal growth factor receptor Homo sapiens 145-149 16373709-11 2005 Significant down-regulation of COX-2 and EGFR expression was observed in the BxPC-3 and HPAC cells treated with the combination of erlotinib (1 micromol/L) and celecoxib (10 micromol/L) compared with celecoxib- or erlotinib-treated cells. Celecoxib 160-169 epidermal growth factor receptor Homo sapiens 41-45 16373709-11 2005 Significant down-regulation of COX-2 and EGFR expression was observed in the BxPC-3 and HPAC cells treated with the combination of erlotinib (1 micromol/L) and celecoxib (10 micromol/L) compared with celecoxib- or erlotinib-treated cells. Celecoxib 200-209 epidermal growth factor receptor Homo sapiens 41-45 15355926-3 2004 EXPERIMENTAL DESIGN: A combination of EGFR-selective tyrosine kinase inhibitors (TKIs) AG1478 or ZD1839 (Iressa or gefitinib) with a Cox-2 inhibitor (Cox-2I) celecoxib (Celebrex) was studied for its effects on cell growth, cell cycle progression, and apoptosis in SCCHN cell lines by cell growth assay, clonogenic assay, flow cytometric analysis, and terminal deoxynucleotidyl transferase-mediated nick end labeling assay. Celecoxib 158-167 epidermal growth factor receptor Homo sapiens 38-42 15355926-3 2004 EXPERIMENTAL DESIGN: A combination of EGFR-selective tyrosine kinase inhibitors (TKIs) AG1478 or ZD1839 (Iressa or gefitinib) with a Cox-2 inhibitor (Cox-2I) celecoxib (Celebrex) was studied for its effects on cell growth, cell cycle progression, and apoptosis in SCCHN cell lines by cell growth assay, clonogenic assay, flow cytometric analysis, and terminal deoxynucleotidyl transferase-mediated nick end labeling assay. Celecoxib 169-177 epidermal growth factor receptor Homo sapiens 38-42